Together, these results demonstrate that treatment with NTP is capable of alleviating cardiac hypertrophy and heart remodeling, and pharmacologically silencing RBMS1 provides proactive treatment strategies for the clinical treatment of cardiac hypertrophy. Here, RBMS1 is linked to cardiac hypertrophy.